Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Development of bispecific antibodies to detect and track neurodegenerative disease progression.
FY 2025-26
Summary
Clinicians lack reliable tools to predict how neurodegenerative diseases like ALS will progress in individual patients, partly because we have few biological markers that reflect brain health in real time. My project aims to develop new radioactive imaging agents, called PET tracers, that can reveal unhealthy neurons in the brain. These tracers use antibody technology combined with a radioactive signal to detect a protein called NrCAM, which is predicted to increase in disease. This is unique from traditional methods that rely on detecting protein aggregates and has potential to improve how clinicians monitor disease and tailor treatment. A second part of my work will focus on discovering other ALS-relevant targets, particularly proteins linked to the most common disease hallmark, TDP-43. Novel TDP-43 relevant targets will be adapted to engineer additional PET tracers. In the long term, I aim to expand this antibody-based technology into a platform not only for detecting disease but also for delivering therapies precisely to affected neurons, opening new avenues for personalized care in ALS.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
Michigan, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
537725
Name
Dubinski Alicia
Region
Michigan
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Development of bispecific antibodies to detect and track neurodegenerative disease progression.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Bispecific Antibodies; Disease Monitoring; Drug Delivery; Mouse Models; Neurodegeneration; Proteomics; Tdp-43
Abstract
Clinicians lack reliable tools to predict how neurodegenerative diseases like ALS will progress in individual patients, partly because we have few biological markers that reflect brain health in real time. My project aims to develop new radioactive imaging agents, called PET tracers, that can reveal unhealthy neurons in the brain. These tracers use antibody technology combined with a radioactive signal to detect a protein called NrCAM, which is predicted to increase in disease. This is unique from traditional methods that rely on detecting protein aggregates and has potential to improve how clinicians monitor disease and tailor treatment. A second part of my work will focus on discovering other ALS-relevant targets, particularly proteins linked to the most common disease hallmark, TDP-43. Novel TDP-43 relevant targets will be adapted to engineer additional PET tracers. In the long term, I aim to expand this antibody-based technology into a platform not only for detecting disease but also for delivering therapies precisely to affected neurons, opening new avenues for personalized care in ALS.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Dubinski, Alicia
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~